CLOs on the Move

Bio-Techne

www.bio-techne.com

 
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne`s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.bio-techne.com
  • 614 McKinley Place NorthEast
    Minneapolis, MN USA 55413
  • Phone: 612.379.2956

Executives

Name Title Contact Details
Trevor Woodage
 Assistant General Counsel, Intellectual Property Profile
Shane Bohnen
 Associate General Counsel Profile
Shane Bohnen
 Senior Vice President and General Counsel Profile
Brenda Furlow
 General Counsel Profile
Brenda Furlow
 Executive Vice President, General Counsel and Chief Sustainability and Compliance Officer Profile

Similar Companies

Beta Bionics

Beta Bionics is proud to be a Massachusetts public benefit corporation.

Tactiva Therapeutics

Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.

Dova Pharmaceuticals

Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re...

Kiromic

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using our proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is in the process of developing a multi-indication allogeneic CAR-T cell therapy that exploits the natural potency of Gamma Delta T-cells to target solid cancers. From our heritage as a cancer vaccine development company, Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. Our pipeline development is leveraged through the Company`s proprietary target discovery engine called "DIAMOND," where big data science meets target identification to dramatically compress the man-years and billions of drug development dollars required to develop a live drug.

Tscan

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.